Diagnos' Andre Larente on the benefits of using AI for the early detection of critical health issues

written by InvestorNews | December 1, 2020

"Our (AI) technology works, its in production (CARA). We are fully funded….the markets we are going after are extremely big…" are excerpts that Andre Larente of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) offered Tracy Weslosky of InvestorIntel in a recent interview.

Tracy starts the interview by identifying the increasing interest from the global market on the Canadian biotech sector. She asks Andre to identify their competitive advantages for investors seeking to understand this market better. Andre explains "we specialize in using AI to tackle some of the medical imaging issues in the world."

Click here to hear the full interview and learn more about how Diagnos offers early detection medical tests for a wide spectrum of critical medical issues that range from diabetes to cardiovascular issues.

About Diagnos:

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence ("AI") tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA's Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.